PT - JOURNAL ARTICLE AU - Emily A. Bruce AU - Margaret G. Mills AU - Reigran Sampoleo AU - Garrett A. Perchetti AU - Meei-Li Huang AU - Hannah W. Despres AU - David J. Shirley AU - Keith R. Jerome AU - Alexander L. Greninger AU - Jason W. Botten TI - Predicting Infectivity: Comparing Four PCR-based Assays to Detect Culturable SARS-CoV-2 in Clinical Samples AID - 10.1101/2021.07.14.21260544 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.14.21260544 4099 - http://medrxiv.org/content/early/2021/07/18/2021.07.14.21260544.short 4100 - http://medrxiv.org/content/early/2021/07/18/2021.07.14.21260544.full AB - With the COVID-19 pandemic caused by SARS-CoV-2 now in its second year, there remains an urgent need for diagnostic testing that can identify infected individuals, particularly those who harbor infectious virus. Various RT-PCR strategies have been proposed to identify specific viral RNA species that may predict the presence of infectious virus, including detection of transcriptional intermediates (e.g. subgenomic RNA [sgRNA]) and replicative intermediates (e.g. negative-strand RNA species). Using a novel primer/probe set for detection of subgenomic (sg)E transcripts, we successfully identified 100% of specimens containing culturable SARS-CoV-2 from a set of 126 clinical samples (total sgE CT values ranging from 12.3-37.5). This assay showed superior performance compared to a previously published sgRNA assay and to a negative-strand RNA assay, both of which failed to detect target RNA in a subset of samples from which we isolated live virus. In addition, total levels of viral RNA (genome, negative-strand, and sgE) detected with the WHO/Charité primer-probe set correlated closely with levels of infectious virus. Specifically, infectious virus was not detected in samples with a CT above 31.0. Clinical samples with higher levels of viral RNA also displayed cytopathic effect (CPE) more quickly than those with lower levels of viral RNA. Finally, we found that the infectivity of SARS-CoV-2 samples is significantly dependent on the cell type used for viral isolation, as Vero E6 cells expressing TMRPSS2 extended the analytical sensitivity of isolation by more than 3 CT compared to parental Vero E6 cells and resulted in faster isolation. Our work shows that using a total viral RNA Ct cut-off of >31 or specifically testing for sgRNA can serve as an effective rule-out test for viral infectivity.Competing Interest StatementALG reports contract testing from Abbot and research support from Merck and Gilead. The other authors declare no conflicts of interest.Funding StatementThis work was supported by NIH P30GM118228-04 (to E.A.B.) and funding from the Office of the Vice President for Research at the University of Vermont (JWB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The excess clinical samples used in this study were approved under a waiver of consent by the University of Washington institutional review board (IRB; STUDY00000408). The de-identified samples were determined to be exempt because they were not considered human subjects research due to the quality improvement and public health intent of the work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available within the manuscript and its supplementary materials. R code is available upon reasonable request.